CD27


Also found in: Wikipedia.

CD27

a type I transmembrane protein present on mature T cells, medullary thymocytes, and some B cells that is a ligand for CD70 and serves as a member of the nerve growth factor family; expressed in chronic lymphocytic leukemia.
References in periodicals archive ?
The mission is: - ensure the support of CD27 in coordination work with key partners, Rector, Eple, - complete physical inventory work equipment in and EPLE analyze, - to define missions calibration (1 st and 2 e ) level - support the creation and formation of an internal team that can provide support and maintenance, - conduct a scoping note for the elected and the General Management, - Develop a master plan digital in EPLE
Preclinical data demonstrate that SGN-70 blocks the interaction between CD70 and its receptor, CD27, and selectively depletes activated CD70-positive lymphocytes.
SGN-70 has been shown in preclinical models to selectively deplete CD70-positive lymphocytes and block the co-stimulation pathway between CD70 and its receptor, CD27.
Promising and possible biomarkers: type I interferon, sVCAM-1, CD27 high plasma cells, soluble IL-2 receptor, BLyS.
Engaging CD27 with the appropriate monoclonal antibody has proven highly effective at promoting anti-cancer immunity and we look forward to translating these results to patients.
Showed that human anti-CD27 mAb inhibited the growth of human tumor cells expressing CD27 in a mouse tumor model.
to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers.
Studies demonstrated that targeting CD27 receptors with Celldex's human anti-CD27 antibodies can increase the numbers of responding T cells and directly impact tumor cells expressing CD27.
In analyzing the data from the trial we sought to detect immune correlates by using multi-parametric flow cytometry to identify 16 unique RCC antigen reactive CTL subsets based on the expression of the surface markers CD28, CD45RA, CD27 and CCR7, present in blood draws collected prior to treatment with AGS-003 or sunitinib and after administration of five doses of AGS-003 in combination with sunitinib.
Nasdaq: CLDX) announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029 entitled "Human immune therapies using a CD27 agonist alone or in combination with other immune modulators" which broadly supports the Company's product candidate CDX-1127.
CDX-1127 has a dual mechanism of action - the antibody can function as an immune modulator through activation of T cells and natural killer cells and it can also function as a conventional antibody by direct activity against tumor cells that express CD27.